Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Zjednodušená léčba plicních exacerbací v pediatrii (STOP PEDS RCT)

Zjednodušená léčba plicních exacerbací v pediatrii Randomizovaná kontrolovaná studie (STOP PEDS RCT)

The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.

Přehled studie

Detailní popis

The STOP PEDS pilot study demonstrated that a randomized trial of treatment strategies for mild pulmonary exacerbations (PEx) in children with CF was feasible and that assignment to a tailored therapy arm (defined below) may reduce antibiotic exposure.

Based on the research priorities identified by CF families and clinicians and the results of the pilot study, the STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient PEx in the pediatric CF population. The two treatment arms are immediate antibiotics and tailored therapy. In both arms, participants will be instructed to increase airway clearance at the onset of an eligible PEx. In the immediate antibiotics arm, they will also begin 14 days of oral antibiotics preselected by their primary CF providers, while in the tailored therapy they will only begin antibiotics if prespecified criteria for worsening symptoms or failure to improve are met.

The STOP PEDS study will enroll three cohorts. In the main cohort, children ages 6-18 on highly effective modulator therapy (HEMT) will be enrolled when well and followed for 12 months. Participants will be randomly assigned to a treatment arm and maintain that treatment assignment for all subsequent eligible PEx during their 12-month enrollment period. Two additional pilot cohorts, the preschool cohort (children ages 3 to 5 on HEMT) and the non-HEMT cohort (children ages 6-18 not eligible for HEMT), will be enrolled in parallel pilot studies. Participants will enroll when well and be followed through one randomized PEx.

Participants in the STOP PEDS RCT at selected sites will have the opportunity to enroll in optional substudies if eligible. These substudies include:

  • Clinic throat swab substudy
  • Home throat and nasal swab substudy
  • Remote monitoring substudy (Home monitoring of lung function, vital signs, activity and sleep)

Typ studie

Intervenční

Zápis (Odhadovaný)

430

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Erika Enright
  • Telefonní číslo: 206-897-1922
  • E-mail: eenright@uw.edu

Studijní místa

    • British Columbia
      • Vancouver, British Columbia, Kanada, V6H 3V4
        • Nábor
        • British Columbia Children's Hospital
        • Vrchní vyšetřovatel:
          • Jonathan Rayment, MD
        • Kontakt:
    • Ontario
      • Toronto, Ontario, Kanada, M5G 0A4
        • Nábor
        • The Hospital for Sick Children & Toronto Canada CF Centre Pediatrics
        • Vrchní vyšetřovatel:
          • Felix Ratjen, MD
        • Kontakt:
    • Alabama
      • Birmingham, Alabama, Spojené státy, 35233
        • Nábor
        • The Children's Hospital Alabama & University of Alabama at Birmingham
        • Vrchní vyšetřovatel:
          • Christopher Fowler, MD
        • Kontakt:
    • Arizona
      • Tucson, Arizona, Spojené státy, 85713
        • Nábor
        • Tucson Cystic Fibrosis Center
        • Vrchní vyšetřovatel:
          • Cori Daines, MD
        • Kontakt:
    • California
      • Los Angeles, California, Spojené státy, 90027
        • Nábor
        • Children's Hospital of Los Angeles & Anton Yelchin Cystic Fibrosis Clinic
        • Vrchní vyšetřovatel:
          • Martha McKinney, MD
        • Kontakt:
      • Palo Alto, California, Spojené státy, 94304
        • Nábor
        • Stanford University
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Lori WaiHang Lee, MD
      • San Diego, California, Spojené státy, 92123
        • Zatím nenabíráme
        • Rady Children's Hospital at University of California San Diego
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Kathryn Akong, MD
    • Colorado
      • Aurora, Colorado, Spojené státy, 80045
    • Georgia
      • Atlanta, Georgia, Spojené státy, 30322
        • Nábor
        • Children's Healthcare of Atlanta & Emory University
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Ajay Kasi, MD
    • Illinois
      • Chicago, Illinois, Spojené státy, 60611
        • Nábor
        • Ann & Robert H. Lurie Children's Hospital of Chicago & Northwestern University
        • Vrchní vyšetřovatel:
          • Maria Dowell, MD
        • Kontakt:
    • Indiana
      • Indianapolis, Indiana, Spojené státy, 46202
        • Nábor
        • Riley Hospital for Children & Indiana University
        • Kontakt:
        • Vrchní vyšetřovatel:
          • D. B. Sanders, MD, MS
        • Kontakt:
    • Iowa
      • Iowa City, Iowa, Spojené státy, 52242
        • Nábor
        • University of Iowa
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Anthony Fischer, MD
    • Maryland
      • Baltimore, Maryland, Spojené státy, 21287
        • Nábor
        • Johns Hopkins Hospital, Johns Hopkins University
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Peter Mogayzel, MD, PhD, MBA
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02115
    • Michigan
      • Ann Arbor, Michigan, Spojené státy, 48109-5212
        • Nábor
        • University of Michigan Health System
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Samya Nasr, MD
    • Minnesota
      • Minneapolis, Minnesota, Spojené státy, 55404
      • Minneapolis, Minnesota, Spojené státy, 55455
        • Nábor
        • The Minnesota Cystic Fibrosis Center & University of Minnesota
        • Vrchní vyšetřovatel:
          • Samuel Goldfarb, MD
        • Kontakt:
    • Missouri
      • Kansas City, Missouri, Spojené státy, 64108
        • Nábor
        • Children's Mercy Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Hugo Escobar, MD
      • St Louis, Missouri, Spojené státy, 63110
        • Nábor
        • St. Louis Children's Hospital & Washington University School of Medicine
        • Vrchní vyšetřovatel:
          • Jessica Pittman, MD
        • Kontakt:
    • New York
      • Rochester, New York, Spojené státy, 14642
        • Nábor
        • University of Rochester Medical Center Strong Memorial
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Matthew McGraw, MD
    • North Carolina
      • Chapel Hill, North Carolina, Spojené státy, 27514
        • Nábor
        • University of North Carolina at Chapel Hill
        • Vrchní vyšetřovatel:
          • Jennifer Goralski, MD
        • Kontakt:
    • Ohio
      • Cincinnati, Ohio, Spojené státy, 45229
        • Nábor
        • Cincinnati Children's Hospital Medical Center
        • Vrchní vyšetřovatel:
          • Gary McPhail, MD
        • Kontakt:
    • Oregon
      • Portland, Oregon, Spojené státy, 97239-3098
        • Nábor
        • Oregon Health & Science University
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Kelvin MacDonald, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Spojené státy, 19104
        • Nábor
        • Children's Hospital of Philadelphia & University of Pennsylvania
        • Vrchní vyšetřovatel:
          • Clement Ren, MD, MBA
        • Kontakt:
        • Kontakt:
      • Pittsburgh, Pennsylvania, Spojené státy, 15224
        • Nábor
        • Children's Hospital of Pittsburgh of UPMC & University of Pittsburgh Medical Center
        • Vrchní vyšetřovatel:
          • Daniel Weiner, MD
        • Kontakt:
    • South Carolina
      • Charleston, South Carolina, Spojené státy, 29425
        • Nábor
        • Medical University of South Carolina
        • Vrchní vyšetřovatel:
          • Sylvia E Szentpeter, MD
        • Kontakt:
          • Anushka Phadke, CRC
          • Telefonní číslo: 843-792-4656
          • E-mail: phadke@musc.edu
        • Kontakt:
    • Texas
      • Dallas, Texas, Spojené státy, 75235
        • Nábor
        • University of Texas Southwestern & Children's Health
        • Vrchní vyšetřovatel:
          • Preeti Sharma, MD
        • Kontakt:
      • Houston, Texas, Spojené státy, 77030
        • Nábor
        • Texas Children's Hospital & Baylor College of Medicine
        • Vrchní vyšetřovatel:
          • Fadel Ruiz, MD
        • Kontakt:
    • Vermont
      • Burlington, Vermont, Spojené státy, 05401
        • Nábor
        • Vermont Children's Hospital & University of Vermont Medical Center
        • Vrchní vyšetřovatel:
          • Thomas Lahiri, MD
        • Kontakt:
    • Virginia
      • Richmond, Virginia, Spojené státy, 23298
        • Nábor
        • Virginia Commonwealth University
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Michael T. Schechter, MD
    • Washington
      • Seattle, Washington, Spojené státy, 98105
    • Wisconsin
      • Madison, Wisconsin, Spojené státy, 53792
        • Nábor
        • University of Wisconsin
        • Vrchní vyšetřovatel:
          • Hara Levy, MD
        • Kontakt:
      • Milwaukee, Wisconsin, Spojené státy, 53226
        • Nábor
        • Children's Wisconsin & Medical College of Wisconsin
        • Vrchní vyšetřovatel:
          • Nicholas Antos, MD
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

3 roky až 18 let (Dítě, Dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Age

    1. For main cohort and non-HEMT cohort: age 6 to <19 years
    2. For preschool cohort: age 3 to <6 years
  2. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:

    1. sweat chloride ≥ 60 mEq/liter
    2. two disease-causing variants in the cystic fibrosis transmembrane conductive regulator (CFTR) gene
  3. Written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability of participant to comply with the requirements of the study

  4. Highly Effective Modulator Therapy

    1. For main cohort and preschool cohort: Taking HEMT for at least 3 months at enrollment
    2. For non-HEMT cohort: not eligible for HEMT based on CFTR genotype or eligible but not taking for at least 3 months and no plans to start HEMT in the next year, and also not taking tezacaftor-ivacaftor or lumacaftor-ivacaftor for at least 3 months
  5. For main cohort and non-HEMT cohort: able to perform acceptable and reproducible spirometry

  6. For main cohort and non-HEMT cohort: ppFEV1 ≥ 50% predicted at enrollment based on the Global lung Initiative (GLI) reference equations

  7. Ability to receive text messages and access the internet

Exclusion Criteria:

  1. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the individual or the quality of the data
  2. Receiving an acute course of oral or IV antibiotics at the time of enrollment or within the 14 days prior to enrollment. Individuals may be re-screened ≥21 days after completion of antibiotics if they are at their baseline state of health, per self-report
  3. Treatment with systemic corticosteroids at enrollment or within the 14 days prior to enrollment. Individuals may be re- screened ≥21 days after completion of systemic corticosteroids if they are at their clinical baseline, per self-report
  4. History of solid organ transplant
  5. History of positive culture for Mycobacterium abscessus in the 12 months prior to enrollment
  6. Treatment with antibiotics for any non-tuberculous mycobacteria (NTM) at enrollment
  7. Three or more IV antibiotic-treated PEx in the 12 months prior to enrollment
  8. Treatment with chronic oral antibiotics other than azithromycin at enrollment
  9. Treatment with systemic corticosteroids for allergic bronchopulmonary aspergillosis (ABPA) in the 12 months prior to enrollment

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Immediate Antibiotics

Increased airway clearance plus early initiation of oral antibiotics

Increase airway clearance and start 14 days of preselected oral antibiotics right away

Experimentální: Tailored Therapy

Increased airway clearance alone, with addition of oral antibiotics for worsening symptoms or failure to improve

Increase airway clearance and start preselected oral antibiotics later if symptoms get worse or do not get better according to prespecified criteria

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
One-year change in pulmonary function by spirometry-measured ppFEV1
Časové okno: 1 year

Compare the difference in pulmonary function between arms by evaluating change in spirometry-measured percent predicted forced expiratory volume (ppFEV1). A spirometry test measures the amount of air a person can forcibly exhale after a deep breath (forced vital capacity, or FVC) and the amount of air they can exhale in one second (forced expiratory volume in one second, or FEV1). A lower measured value compared to the reference value indicates lung disease.

1 year

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
One-Year change in pulmonary function by LCI
Časové okno: 1 year

Compare the difference in pulmonary function between arms by evaluating change in Lung Clearance Index (LCI). LCI increases when there is lung disease, which causes ventilation inhomogeneity. LCI is calculated as the number of lung volume turnovers (cumulative expired volume divided by the functional residual capacity [FRC]) required to reduce end-tidal nitrogen concentration to 1/40th of the original level.

1 year

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Recovery to baseline by ppFEV1 and CRISS following a PEx
Časové okno: 28 days

Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx), by spirometry-measured percent predicted forced expiratory volume (ppFEV1), and after all pulmonary exacerbations, measured by CRISS symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

28 days
Recovery to baseline by Lung Clearance Index (LCI)
Časové okno: 28 days

Compare recovery to baseline between arms over the 28-day period after the first pulmonary exacerbation (PEx) in LCI, and after all exacerbations for symptom scores. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

28 days
Safety Endpoint 1: Cumulative oral antibiotic exposure
Časové okno: 1 year

Compare cumulative oral antibiotic exposure in each treatment arm.

1 year
Safety Endpoint 2: Number of respiratory illnesses
Časové okno: 1 year

Compare the number of respiratory illnesses reported over the study period in each treatment arm.

1 year
Safety Endpoint 3: Proportion of respiratory illnesses treated with antibiotics during PEx
Časové okno: 28 days

Compare the proportion of respiratory illnesses treated with antibiotics during the 28-day pulmonary exacerbation (PEx) treatment period in each treatment arm.

28 days
Safety Endpoint 4: Number of PEx treated with IV antibiotics
Časové okno: 1 year

Compare the number of pulmonary exacerbations (PEx) treated with IV antibiotics over the study period in each treatment arm.

1 year
Safety Endpoint 5: Proportion of PEx failing to recover to baseline symptoms at Day 28
Časové okno: 28 days

Compare the proportion of pulmonary exacerbations (PEx) failing to recover to baseline symptoms at Day 28 in each treatment arm.

28 days
Safety Endpoint 6: Proportion of PEx with ppFEV1 below baseline at Day 28
Časové okno: 1 year

Compare the proportion of pulmonary exacerbations (PEx) with spirometry-measured percent predicted forced expiratory volume (ppFEV1) below baseline at Day 28 in each treatment arm.

1 year
Safety Endpoint 7: Time from initial randomized PEx to next respiratory illness
Časové okno: 1 year

Compare the time from initial randomized pulmonary exacerbation (PEx) to next respiratory illness in each treatment arm.

1 year
Safety Endpoint 8: Targeted adverse events (patient report of antibiotic side effects during PEx)
Časové okno: 1 year

Compare the targeted adverse events (patient report of antibiotic side effects during pulmonary exacerbation period) in each treatment arm.

1 year
Safety Endpoint 9: Treatment-emergent CF microorganisms on clinical respiratory cultures
Časové okno: 1 year

Compare treatment-emergent CF microorganisms on clinical respiratory cultures in each treatment arm.

1 year
Qualitative Assessment 1: Caregivers' experience managing study treatment
Časové okno: 1 year

To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences.

1 year
Qualitative Assessment 2: Study treatment impact on child and family daily life
Časové okno: 1 year

To understand benefits and challenges associated with assigned treatment through targeted qualitative interviews of caregivers we will evaluate study treatment impact on child and family daily life and report themes that emerge regarding caregivers' experiences.

1 year
Health care costs 1: Total estimated cost of antibiotics
Časové okno: 1 year

Compare total estimated cost of antibiotics used over the course of the study between treatment arms.

1 year
Health care costs 2: Health care utilization
Časové okno: 1 year

Compare health care utilization over the course of the study between treatment arms, including number of primary care visits and number of emergency room visits.

1 year
Health care costs 3: Parent work productivity measures (WPAI)
Časové okno: 1 year

To compare parent Work Productivity and Activity Impairment (WPAI) measures between study arms. The WPAI includes four scores assessing absenteeism, presenteeism, work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment in the last seven days. Scores range from 0 to 100, with higher scores indicating greater impairment.

1 year
Preschool and non-HEMT Pilot Cohort Primary Feasibility
Časové okno: 28 days

Estimate the proportion of preschool and non-HEMT (Highly Effective Modulator Therapy) participants randomized to the tailored therapy arm that has no antibiotic exposure in the 28 days following a pulmonary exacerbation (PEx).

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 1: ppFEV1 and LCI recovery
Časové okno: 28 days

Compare percent predicted forced expiratory volume (ppFEV1) and Lung Clearance Index (LCI) recovery using Day 28 values compared to nearest pre-PEx baseline measure in both treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 2: Time to symptom recovery
Časové okno: 28 days

Compare time to symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 3: Targeted adverse events
Časové okno: 28 days

Compare targeted adverse events (participant report of antibiotic side effects during PEx period) between treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 4: Treatment-emergent CF microorganisms
Časové okno: 28 days

Compare treatment-emergent CF microorganisms on clinical respiratory cultures between treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 5: Treatment with additional non-protocol assigned antibiotics
Časové okno: 28 days

Compare treatment with additional non-protocol assigned antibiotics within the 28 days post-randomization between treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort Safety Endpoint 6: Time to IV antibiotics following a randomized PEx
Časové okno: 28 days

Compare time to IV antibiotics following a randomized PEx (using CF Foundation Patient Registry data, if available) between treatment arms.

28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 1
Časové okno: 28 days

Measure the proportion of approached patients that enrolls.

28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 2
Časové okno: 28 days

Measure the proportion of respiratory symptoms meeting randomization criteria.

28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 3
Časové okno: 28 days

Measure the proportion of respiratory symptoms meeting randomization criteria resulting in treatment initiation within assigned arm.

28 days
Preschool and non-HEMT Pilot Cohort: Future Larger Clinical Trial Feasibility 4
Časové okno: 28 days

Through targeted qualitative interviews of caregivers we will describe caregivers' experience managing study treatment and report themes that emerge regarding caregivers' experiences in order to understand motivations, benefits and challenges associated with assigned treatment arm.

28 days
Clinic Throat Swab Substudy 1: Metagenomic Sequencing
Časové okno: 1 year

Use quantitative polymerase chain reaction (qPCR) and metagenomic sequencing to quantitatively define throat swab microbiology at baseline, at exacerbation diagnosis, and after treatment. Metagenomic sequencing analyzes the genomes of all microorganisms in a sample, providing a broad overview of the ecosystem's composition. It can be used to study the diversity of bacteria, detect the abundance of microbes, and study unculturable microorganisms.

1 year
Clinic Throat Swab Substudy 2: Microbiota Measures
Časové okno: 1 year

Correlate throat microbiota measures (both pre-treatment microbial taxonomic or functional gene abundances, and changes in those abundances) with clinical outcome measures within antibiotic treatments.

1 year
Home Throat and Nasal Swab Substudy 1: Feasibility of Home Collection of Nasal Swabs for Viral Testing and Illness Frequency
Časové okno: 28 days

Assess the feasibility of home collection of nasal swabs for viral testing at the time of pulmonary exacerbation (PEx) and determine the frequency of viral illness at the time of PEx diagnosis.

28 days
Home Throat and Nasal Swab Substudy 2: Feasibility of Home Collection of Throat Swabs for Bacterial testing
Časové okno: 28 days

Assess the feasibility of home collection of throat swabs for bacterial testing at the time of pulmonary exacerbation (PEx).

28 days
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and Symptom recovery
Časové okno: 28 days

Evaluate the association between the presence of viral illness and symptom recovery (number of days to recover to baseline CRISS score) between treatment arms. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

28 days
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and FEV1
Časové okno: 28 days

Evaluate the association between the presence of viral illness and spirometry-measured forced expiratory volume (FEV1) at Day 28.

28 days
Home Throat and Nasal Swab Substudy 3: Association Between Viral Illness and antibiotic treatment.
Časové okno: 28 days

Evaluate the association between the presence of viral illness and the percent of subjects in the tailored therapy arm requiring antibiotic treatment.

28 days
Home Throat and Nasal Swab Substudy 5: Bacterial Pathogen Identification, Frequency and Impact on Treatment Changes
Časové okno: 28 days

Determine the concordance of bacteria identified on CF pathogen testing at the time of pulmonary exacerbation (PEx) compared to the most recent routine clinic visit. In addition, assess how frequently new bacterial pathogens are identified at the time of PEx and how this impacts treatment changes, including the need to change or add antibiotic therapy.

28 days
Remote Monitoring Substudy 1: Feasibility of Home Spirometry Use During PEx
Časové okno: 28 days

Describe the feasibility and user acceptability of home spirometry during pulmonary exacerbations (PEx) in children with CF via survey of participants at the end of the study.

28 days
Remote Monitoring Substudy 2: Feasibility of BioButton Use During PEx
Časové okno: 14 days

Describe the feasibility and user acceptability of BioButton use during pulmonary exacerbations in children with CF via survey of participants at the end of the study.

14 days
Remote Monitoring Substudy 3: Change in FEV1 by Home Spirometry
Časové okno: 28 days

Describe the change from nearest baseline-state FEV1 to Day 0 exacerbation state measurement and the trajectory of change during the exacerbation state (through Day 28).

28 days
Remote Monitoring Substudy 4: Compare Home Spirometry vs. Clinic Spirometry Measures
Časové okno: 28 days

Compare measurements and their change measured by home spirometry vs. clinic spirometry during the exacerbation state.

28 days
Remote Monitoring Substudy 5: BioButton-measured Change in Resting Heart Rate During PEx
Časové okno: 14 days

Describe changes in resting heart rate from Day 0 to 14 of the exacerbation state.

14 days
Remote Monitoring Substudy 5: BioButton-measured Change in Resting respiratory rate During PEx
Časové okno: 14 days

Describe changes in Resting respiratory rate from Day 0 to 14 of the exacerbation state.

14 days
Remote Monitoring Substudy 5: BioButton-measured Change in Activity Level During PEx
Časové okno: 14 days

Describe changes activity level, measured using actigraphy, and summarized as the mean (SD) number of active minutes in a day, from Day 0 to 14 of the exacerbation state.

14 days
Remote Monitoring Substudy 5: BioButton-measured Change in Sleep During PEx
Časové okno: 14 days

Describe changes in sleep time from Day 0 to 14 of the exacerbation state.

14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in resting heart rate During PEx with Baseline Averages
Časové okno: 14 days

Compare changes in resting HR to averages from a 7-day period during baseline state.

14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Resting respiratory rate During PEx with Baseline Averages
Časové okno: 14 days

Compare changes in BioButton-measured Resting respiratory rate to averages from a 7-day period during baseline state.

14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in activity level During PEx with Baseline Averages
Časové okno: 14 days

Compare BioButton-measured change in activity level during pulmonary exacerbation (PEx) to averages from a 7-day period during baseline state.

14 days
Remote Monitoring Substudy 6: Compare BioButton-measured Change in Sleep During PEx with Baseline Averages
Časové okno: 14 days

Compare BioButton change in sleep during PEx to averages from a 7-day period during baseline state.

14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Heart Rate (HR)
Časové okno: 14 days

Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Heart Rate (HR). The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Resting Respiratory rate
Časové okno: 14 days

Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Resting Respiratory rate. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Activity level
Časové okno: 14 days

Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to Activity level, measured with actigraphy. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

14 days
Remote Monitoring Substudy 7: Determine correlations between changes in FEV1 and CRISS to Sleep duration
Časové okno: 14 days

Determine correlations between changes from Day 0 to 14 in forced expiratory volume (FEV1) and CRISS score to sleep duration. The Chronic Respiratory Infection Symptom Score (CRISS) ranges from 0 to 100, with higher scores indicating more symptoms.

14 days

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Spolupracovníci

Vyšetřovatelé

  • Vrchní vyšetřovatel: Margaret Rosenfeld, MD, MPH, Seattle Children's Hospital
  • Vrchní vyšetřovatel: D. B. Sanders, MD, MS, Indiana University

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

1. prosince 2024

Primární dokončení (Odhadovaný)

30. prosince 2027

Dokončení studie (Odhadovaný)

28. února 2029

Termíny zápisu do studia

První předloženo

14. října 2024

První předloženo, které splnilo kritéria kontroly kvality

21. října 2024

První zveřejněno (Aktuální)

23. října 2024

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

9. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

6. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit